[Open clinical trial in dermal mycoses of a 1% ciclopiroxolamine solution in polyethylene glycol 400 carried out in FR Germany/Study with shortened therapy (author's transl)].
In an open multicentre study, a 1% solution of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt (ciclopiroxolamine, Cic. Hoe 296, Batrafen) in polyethylene glycol 400 was examined for its topical activity in 344 cases of dermal mycoses. 65.4% of them were caused by dermatophytes and 19.2% by yeast-like fungi. In most cases, the treatment period was two weeks, with one or two daily applications. The examiners found global therapeutic effectiveness in 97.5% of the mycoses, the rate of very good and good results being 84.0%, and a very good tolerance in 99.0%. Individual side effects were predominantly subjective and transient.
D000287:Administration, Topical; D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077768:Ciclopirox; D002986:Clinical Trials as Topic; D003881:Dermatomycoses / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*; D012996:Solutions
D000935:Antifungal Agents; D011728:Pyridones; D012996:Solutions; D000077768:Ciclopirox
Offene Prüfung einer 1% igen Ciclopiroxolamin-Lösung auf Polyethylenglykol 400-Basis bei Dermatomykosen in der Bundesrepublik Deutschland. Studie mit verkürzter Therapiedauer.